It's not unique to Theranos.
It's all part of the perverse incentives involved with well-funded tech companies.
There is no real incentive to call out fraud. As an investor or a partner you might pass on a deal, but to go public with your concerns means risking a possible lawsuit, raising the ire of the people who are already on the bandwagon, being excluded from future deals, and being dismissed as someone who is out of touch and "not getting it."
Contrarians can short publicly-traded companies, so there is a financial incentive to call out BS, but for private companies there is very little upside in raising concerns publicly.
If you doubt this effect, contrast the number of articles talking about how blockchain is the future with those taking a hard look at blockchain's financial viability for specific applications. The former group are the ones being asked to speak at conferences and landing large consulting contracts.